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Abstract
Delta relaxation enhanced magnetic resonance (dreMR) is a novel imaging
method capable of producing contrast proportional only to the concentration of the bound
form of the targetable contrast agent using a dynamic field-cycling technique. The
characteristic high relaxivity magnetic field dependence of bound paramagnetic contrast
agents enables suppression of tissue contrast from unbound agents and unenhanced tissue,
thereby increasing probe specificity. The dreMR technique requires an auxiliary actively
shielded field-shifting insert electromagnet to modulate the strength of the main clinical
magnetic field as a function of time during the relaxation and evolution periods of a pulse
sequence.
Ablavar (approved for human use) binds specifically to serum albumin and has a
strong magnetic field dependence for serum albumin around 1.5T. Native biological
tissues and unbound Ablavar demonstrate very little magnetic field dependence. Using a
custom dreMR preparatory pulse, where the strength of the B0 field is modulated for
different times, signal intensity from only the bound form of Ablavar can be produced.
This work entails further advancement of the dreMR method, where we
investigate developing the dreMR contrast using phantoms loaded with and without
Rabbit Serum Albumin and in vivo imaging using mouse subjects with prostate and breast
cancer.
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Agent.
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Chapter 1
General Introduction
1.1 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a diagnostic imaging modality that has
steadily evolved since the 1970’s to provide unparalleled access to imaging of biological
systems (1, 2). MRI is non-invasive, does not deliver ionizing radiation, and provides
excellent spatial resolution. Its primary weakness is its low sensitivity and specificity,
which can be improved with the use of contrast agents (1). MRI relies on the interaction
of nuclear spin systems with an applied magnetic field (3).

Applications and

manipulation of various pulse sequences and magnetic field gradients provide anatomical
images with superb soft tissue contrast. Modern MRI techniques not only allow for
imaging of anatomy and pathology, but also the investigation of organ function and in
vivo biochemistry.
This thesis entails the development and application of a novel magnetic resonance
(MR) molecular imaging method called delta relaxation enhanced Magnetic Resonance
(dreMR, pronounced “dreamer”) (4). Acting as both a device and method, dreMR uses
field-cycling MR techniques in conjunction with clinical superconducting MRI systems to
prepare image contrast related to the concentration of targeted contrasts agents that have
bound to their targeted molecules. The characteristic large magnetic field dependency of

1

relaxivity (

) of bound targeted paramagnetic contrast agents enables contrast

suppression of unbound agents and unenhanced tissues contrast, thereby increasing the
agents’ specificity.

The dreMR method requires additional specialized hardware to

modulate the strength of the main clinical magnetic field to produce the dreMR contrast.
An auxiliary, actively-shielded field-shifting insertable electromagnet is used to modulate
the strength of the main clinical magnetic field as a function of time during the relaxation
and evolution periods of a pulse sequence.

The introductory chapter provides the

necessary background for understanding both MRI and the dreMR principle and method,
introducing MRI, field-cycling relaxometry, and field-cycling MRI concepts, as well as
the principles of relaxation of MRI contrast agents and the potential to increase molecular
specificity with magnetic field-cycling.

1.2 Principles of Magnetic Resonance Imaging
The basis of MRI relies on the interactions of nuclear spin systems with an
external magnetic field. The dominant and most commonly observed nucleus in MRI is
the proton of the water molecule, which possesses an intrinsic nuclear spin of ½. Nuclear
spin is a fundamental physical property which determines if the nuclei will be observable
by MRI. The nuclear spin is comprised of the total sum of the individual contributions of
both unpaired protons and neutrons, each exhibiting a ½-nuclear spin. Only nuclides that
possesses non-zero spin value are observable by MRI.

The spin of any nuclide is

proportional to its magnetic moment, ,
(1.1)

2

where

is the gyromagnetic ratio and I is the spin quantum number. When the magnetic

moment is placed in an external magnetic field, nuclei with non-zero spin will
preferentially align themselves (to a small degree) with the magnetic field, represented by
convention along the z-axis. When measured, (as in quantum mechanics) the magnetic
moment will precess around the z-axis in one of two directions, parallel or antiparallel
with the magnetic field. Within the bulk magnetization of the spins, a little more than
half of the spins will preferentially align parallel with the external field, the lower energy
state, producing a small net magnetization along the direction of the magnetic field,
illustrated in Fig. 1.1. In the absence of a magnetic field, the magnetic moments of an
ensemble of spins would be randomly distributed and produce a net magnetization of
zero.

Figure 1.1 Left: Magnetic moments of a spin population in the presence of an external
magnetic field (B0). Each magnetic moment precesses around the z-axis at the Lamor
frequency. Right: The spins are aligned, producing a net magnetization parallel with B0.

Within the bulk magnetization, while in the presence of an external magnetic field,
individual nuclides will precess and resonate at a specific angular frequency, called the
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Lamor frequency.
frequency,

The magnetic moment, μ, will precess around

at the Lamor

, given by
(1.2)

Figure 1.2 Magnetic moment of a nuclide in the presence of an external magnetic ﬁeld
precessing along the axis of the applied ﬁeld (z-axis) at the Larmor frequency (ω0).

MRI relies on the ability to manipulate the interaction of the bulk magnetization of spins
with the external field produced by the superconducting MR magnet.

1.2.1 Signal
An MRI signal arises from the difference in energy absorbed or emitted during
transitions between the two spatially oriented states. The energy of each state is given by
Ɛ, illustrated in Equation 1.3, where I = ±½, and thus the difference between the two
states, ΔƐ, can be calculated from Equation 1.4. For the nuclide to transition to the higher
energy state, Ndown (anti-parallel), sufficient electromagnetic energy, ΔƐ, must be applied.
Similarly, for the nuclide to transition to the lower energy state, Nup (parallel), sufficient
electromagnetic energy, ΔƐ, must be emitted to conserve energy of the spin system. The
ratios of the spin populations between the two orientation states, where Nup and Ndown are

4

the spin population parallel and anti-parallel to the magnetic field respectively, can be
calculated using the Boltzmann distribution (Equation 1.5),

(1.3)
(1.4)
(1.5)

is Planck’s constant divided by 2π, kB is the Boltzmann constant,

where

1.3805 × 10-23 J K-1, and T is the temperature in Kelvin. The net magnetization, M0, is
derived from the difference between the spin orientation states, illustrated in Equations
1.6 to 1.8.

(1.6)
(1.7)
(1.8)

The ratio demonstrates that the net magnetization varies inversely with the temperature,
and directly with the proton density (ρ), the gyromagnetic ratio, and the applied magnetic
field.
In the bulk spin population, the individual spins will rotate at random phases
around the z-axis when placed in a magnetic field. Coherence of the spins can be
achieved when a 90° radio frequency (RF) pulse, B1, is applied at the Lamor frequency
with a transmit RF coil. When the application of the RF pulse is applied for a sufficient

5

duration, the net magnetization will be flipped to precess at the same phase about the zaxis of the magnetic field in the x-y plane inducing a time varying magnetic field. From
Faraday’s law of induction, a voltage can be measured using an RF receiver coil sensitive
to only the magnetization perpendicular to B0 (in the x-y plane). The voltage signal
detected by the receiver RF coil would be proportional to the amplitude of M0 and precess
at the Lamor frequency. The spins would precess about B0 until the RF field is removed,
thereupon the spin-relaxation processes would cause loss of coherence due to dephasing
as magnetization returns to its equilibrium position parallel to the magnetic field. As the
spins return to equilibrium (spin-lattice relaxation), the amplitude of M0 would decay
exponentially and produce a free induction decay (FID) signal, illustrated in Fig. 1.3.

Figure 1.3 Coherence of spins following a 90° B1 RF pulse. Left: Boltzmann distributions
of N and Nspins in presence of magnetic field. Middle: Following an RF pulse, the net
magnetization is flipped into the x-y plane and precesses at the Lamor frequency. Right:
FID signal induced in an RF coil.

1.2.2 Relaxation Times
Immediately after the excitation of the bulk magnetization, whereby sufficient RF
energy is applied to convert the longitudinal magnetization to the transverse plane (x-y
plane), relaxation mechanisms act on the spin system as it relaxes back to equilibrium.
6

The two predominant features of relaxation following the RF pulse include: the dephasing
of the spins due to differences in their precessional frequencies and magnetic field
inhomogeneities, and the regrowth and realignment to their equilibrium orientation along
the z-axis parallel to the magnetic field. Following the loss of energy absorbed from the
RF pulse, the longitudinal magnetization relaxes (spin-lattice relaxation) to the
equilibrium orientation parallel to the z-axis of the magnetic field with a time constant

.

At the same time, the transverse magnetization decays exponentially and relaxes (spinspin relaxation) with a time constant

. The relaxation times vary with magnetic field

strength and temperature. The difference between the time constants,
important for development of contrast in MR imaging.
substantially different

and

and

, are

Biological tissues exhibit

values, and the additional administration of contrast

agents can further enhance these values. Generally, tissues with short

times yield

greater signal intensity (brighter) than those with longer values due to a larger equilibrium
magnetization (

), and tissues possessing short

yield lower signal intensity (darker)

due to a reduction in the detected transverse magnetization. The MR signal from an
image is therefore dependent on the combination of the intrinsic tissue properties and
extrinsic user-selected imaging parameters and contrast agents. The choice of specific
pulse sequences with optimized parameters can be used to exploit tissues contrast and
improve image quality.

7

Figure 1.4 Longitudinal (
McRobbie, DW. 2007).

) and Transverse (

) relaxation rate curves. (Adapted from

1.2.3 Longitudinal Relaxation Time, T1
At equilibrium, the bulk magnetization produces a net magnetization,
with the external magnetic field,

, parallel

. The longitudinal ( ) relaxation, also known as

spin-lattice relaxation, is described as the re-establishment of the equilibrium longitudinal
magnetization

, along the z-axis following the application of a 90° RF pulse. The

relaxation process, results in a loss of the absorbed RF energy to the spin system and the
surrounding environment (lattice). The relaxation process emerges from the fluctuations
in the local magnetic field due to the interactions between the spins and their environment
as the molecule tumbles.

The

relaxation time is given by Equation 1.9, and is

described as the time, , needed for z-component of the magnetization to recover to 63%
of

(Fig. 1.4).
(1.9)
times can be accurately measured by a simple NMR technique where

sequential 90° RF pulses are applied with changing delay times, τ, in-between to examine
8

the

recovery (Fig. 1.5). Repeating the sequence for multiple delay times, the

time

can be determined by plotting the area under the FID versus τ, and fit with an
exponentially decay function to extract the time constant

(5).

Figure 1.5 The Longitudinal Relaxation Experiment.

1.2.4 Transverse Relaxation Time, T2
In the same time that
transverse magnetization,

relaxation occurs, where

recovers to equilibrium, the

, decreases exponentially due to the dephasing of spins

throughout the spin systems. The transverse ( ) relaxation, also known as spin-spin
relaxation, occurs following the application of a 90° RF pulse, where the spins dephase
due to differences in their precessional frequencies.
following a 90° RF pulse, whereas

relaxation occurs immediately

relaxation occurs following 90°-180° sequential RF

pulses (also known as a spin echo sequence). The combined effects of the imperfections
in the main magnetic ﬁeld and the spin-spin interactions lead to the transverse
magnetization decay.

The relaxation process emerges from the molecular size and

mobility of the tumbling molecules, where fast tumbling mobile molecules are able to
average out the field inhomogeneities and intrinsic spin dephasing (leading to longer
times), and large slow tumbling immobile molecules readily experience spin interactions
9

and field inhomogeneities (leading to shorter

times) (2, 5). The

relaxation time is

given by Equation 1.10, and is described as the time needed to recover to 37%
of

(Fig. 1.4).
(1.10)

times can be accurately measured by a simple NMR technique where
sequential 90°-180° RF pulses are applied with changing delay times, τ, in-between to
examine the

decay (Fig. 1.6). The initial 90° RF pulse flips the net magnetization

onto the transverse plane, where the spins begin to dephase at the Lamor frequency. The
subsequent application of the 180° RF pulse refocuses the spins and forms an echo,
allowing for detection of the FID signal. True

decay however is determined from

multiple 180° refocusing pulses, where the transverse signal will decay with the

time

constant and can be determined by plotting the data points from the decay curve (5). The
single FID signal acquired from one 90°-180° RF pulse decays with a
which is dependent on the magnet and its field imperfections.

Figure 1.6 The Transverse Relaxation Experiment.
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decay constant,

1.3 Contrast Agents
The contrast from MR images can be manipulated by changing the intrinsic
biological tissues relaxation processes or the extrinsic user-selected pulse sequence
parameters. The driving force for the use of contrast agents in MRI is to further enhance
and/or differentiate signals arising from the biological tissues of interest. In the clinical
practice, approximately 35% of all MRI examinations are performed with contrast
agents (6, 7). Contrast agents are pharmaceutical drugs that directly affect the magnetic
properties of water protons within their vicinity by increasing the protons’ relaxation
rates. Contrast agents are administered intravenously and exhibit properties such that
they are highly soluble, well-tolerated, and chemically inert (chelated metal ions), and are
rapidly eliminated from the body following the examination (8). The majority of contrast
agents are chelates containing either Gd(III), Fe(III), Mn(II), or iron oxide ions (7-9).
Paramagnetic (Gd(III), Fe(III), Mn(II)) contrast agents predominantly accelerate the
relaxation process, resulting in positive signal enhancement, while superparamagnetic
(iron oxide) contrast agents predominantly accelerate the

relaxation process, resulting

in negative signal enhancement (10). Gadolinium(III) is the most used and studied metal
ion for use in MRI because of its seven unpaired electrons and ideal structural symmetry
(8, 11). Due to the large molar concentrations required to allow for sufficient proton
relaxation (10 -100 μM) (9, 12), the metal ion complex must be chelated to reduce acute
and chronic toxicity and increase in vivo stability and excretability (9).

Recent

developments have seen the ability to modify the chelating agent to increase target
specificity by including selective binding biological vectors (7, 13).
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In addition to the signal enhancement classiﬁcation (

vs

action), all contrast

agents can be divided based on their site of action: extracellular, organ-speciﬁc, or
intravascular agents (10).

Extracellular contrast agents distribute non-specifically

throughout the plasma and interstitial space of the body (8), organ-speciﬁc contrast agents
accumulate specifically in the targeted organ, and intravascular agents enhance the
arterial and vascular structure for the period of the MRI exam (12).
development of contrast agents have been focused on

Historically,

-based contrast agents, since the

relaxation times are typically ﬁve times longer than T2 and therefore easier to shorten
(8, 10).

1.3.1 Relaxivity
The largest challenge in MR imaging is its relatively low sensitivity. As a result
of the high concentration of commercial contrast agents (millimolar concentration)
required to affect the relaxation rates of protons, there have been great efforts to increase
the contrast sensitivity (8). The ability of a contrast agent to change the relaxation rate is
characterized as its relaxivity,

. Relaxivity is defined as the efficiency with which the

contrast agent enhances the proton relaxation rates (9).

(1.11)

where Ri is the inverse of the relaxation time, , known as the relaxation rate, and [CA] is
the concentration of the contrast agent on a per Gd(III) basis. High relaxivity agents can
be detected at lower doses and provide greater contrast at equivalent doses to current
commercial agents with lower relaxivity (1, 8, 14). The two approaches to increasing the
12

relaxivity of contrast agents are to either increase the intrinsic molecular parameters that
govern their relaxivity or to attach multiple metal (generally Gd(III)) ions within the
complexes (1, 9). Attaching multiple metal complexes together to the molecular structure
increases the agents’ relaxivity by reducing the molecular tumbling, τr, due to an increase
in molecular size. The interaction between the Gd(III) and the water molecules becomes
more efficient by reducing the molecular tumbling, τr thereby increasing the effect on
local relaxation rates (13). The intrinsic molecular parameters that govern relaxivity
include hydration number, q, the distance between the Gd(III) ion and the water proton,
the water exchange rate, the electronic relaxation time,
time,

, and the rotational correlation

. (11, 15). Relaxation rates of water protons under the influence of Gd(III) are

largely dominated by inner-sphere relaxivity, resulting from the dipolar contributions due
to interactions with random fluctuations of the electronic field (15). The longitudinal
relaxation arising from the inner-sphere relaxation can be modeled using a modified
Solomon-Bloembergen-Morgan equation formulated by R. Lauffer (9) given by

M

(1.11)

2

where [M] is the molar concentration of the paramagnetic ion, [H2O] is the molar
concentration of water, qIS is the inner-sphere hydration number , T1M is the relaxation
time for bound inner-sphere water molecules and τm is the water residency time. Innersphere relaxation is inversely proportional to the metal-ion-proton distance to the 6th
power. Achieving a reduced distance between the Gd(III) ion and bound protons in
principle would increase relaxivity, since the inner-sphere relaxation is inversely
13

proportional to the metal-ion-proton distance to the 6th power. Reducing the metal-ionproton distance would also allow for rapid exchange between the bound protons and the
free water and efficiently distribute the relaxation effects (1, 11). All commercially
approved Gd(III) contrast agents have one inner-sphere binding site, qIS, for water
protons.

The ability to increase qIS would increase relaxivity, as they are linearly

proportional, however contrast agents that allow multiple binding sites for protons in their
first coordination sphere experience reduced stability and increased concerns for toxicity
(14). The rotational correlation time,
correlation time,

, is largely dependent on the molecular tumbling

, the electronic relaxation time,

, and the chemical exchange,

.

Field strength, molecular structure, and the biochemical environment dominate the
efficiency of these time constants and contribute to the overall chemical exchange
between the contrast agent, water proton, and bulk protons (1, 6, 14). Essentially, the
contrast agent must be stable and chemically inert, allow for fast water exchange from the
first coordination sphere, and efficiently relax the protons it contacts.

Figure 1.7 Parameters influencing relaxivity. (Adapted from Hermann, P et al., 2008).
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1.3.2 Targeted Contrast Agents
The development of targeted contrast agents involves optimizing both their
affinity and speciﬁcity for its protein target (8).

The challenge of synthesizing

compounds with both high target afﬁnity and relaxivity is an ongoing field of interest in
medical chemistry (12). With the large micromolar doses required for sufficient contrast
enhancement, current agents are limited to sites where accumulations of high
concentrations are expected. Detection at the cellular and/or sub-cellular level would
require nanomolar sensitivity, so that conventional Gd(III) agents are suitable (16). New
generations of contrast agents are being developed to be site-specific and with increased
tissue specificity, and as a result, higher relaxivities are required to compensate for the
decrease in concentration needed to detect cellular and sub-cellular bioactivity (1, 6, 1517).
Targeted contrast agents are defined by their mechanism of action, targeting either
passively or actively. Passive targeting favours the specific distribution characteristics of
tissues and cells and are generally either phagocytosed by macrophages or incorporated
into components of the mononuclear phagocyte system (11, 13, 18). Active targeting
selectively binds to molecular targets expressed within various diseases models including
cell surface markers on immune cells or speciﬁc markers speciﬁcally expressed in certain
stages of disease (11, 13, 18). Synthesizing compounds for targeted binding (through
proteins, antibodies, or small peptides) improves relaxivity by slowing down the tumbling
rate of the agent, thereby improving the agents’ specificity.

owever the binding process

is not always an effective strategy since binding to a large biomolecule can also alter the
hydration number and water exchange rate within the inner-sphere (11) reducing the
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inherent relaxivity of the agent. The challenges to maintain and/or improve the agents’
relaxivity upon binding to their target biomolecule is evident by the limited number of
contrast agents approved for clinical use with MRI by the Food and Drug Administration
(FDA), European Medicines Agency (EMEA), and Health Canada. In addition to the
large target affinity, targeted contrast agents exhibit a strong relaxivity change in
magnetic field dependence in both their targeted and non-targeted states (1, 6, 8-12, 14,
15, 17-21). Ablavar (Gadofosveset trisodium, (formerly known as MS-325 and Vasovist)
Lantheus Medical Imaging, Inc. N. Billerica, MA, USA) binds to serum albumin and is
the only current clinically available targeted MRI contrast agents available on the market.
EP-2104R (EPIX Pharmaceuticals, Lexington, Massachusetts, USA) binds to fibrin (21),
and is currently undergoing clinical phase trials. Ablavar differs from other polymeric
Gd(III) complexes, most notably Albumin-GdDTPA.

Albumin-GdDTPA, bound

covalently to albumin, was a prototypical intravascular blood pool contrast agent that
promised favorable contrast for vascular imaging; however, it was not approved for
clinical use due to its poor stability, renal excretion rates, and low water solubility (7).
Albumin and fibrin are useful targeting moieties due to their micromolar
concentrations, and specific pathological presence that can aid in specificity (19, 21). The
most abundant protein in the blood plasma at concentration of 600-700 μM, albumin
reversibly binds noncovalently with Ablavar to provide enhanced

contrast (19). The

reversible binding to albumin controls the leakage of the contrast agent to the
intravascular space, allows for the nontargeted fraction to be filtered through excretion to
the kidneys, protects the targeted fraction from filtration, and increases the agents’
relaxivity approximately 10-fold at 20 MHz (for HSA) upon binding to the larger albumin
molecule (67 kDa) (19, 20). Ablavar has moderate affinity for HSA, with reported
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circulating concentrations of 0.1 mM, 88% of the administered Ablavar is noncovalently
bound to HSA (19, 20), and in vivo studies have shown strong enhancement 1-hour post
injection for animals and 24 hours for humans(19, 20). Originally used to measure liver
function, nutritional status and diseases (Kawasaki, Pancreatitis) (22), recent evidence has
shown albumin as a marker for angiogenic blood vessels presenting a major role in tumor
microenvironment trafficking in and out of tumors, (23-26).
The high sensitivity and specificity of targeted contrast agents makes them
advantageous for molecular imaging, however a major concern with regards to MRI not
readily experienced in other imaging techniques (nuclear, optical), is the enhanced signal
present from tissue in the vicinity of unbound agent and even signal from unenhanced
background tissue (18). The issue is complicated by the high level of competing signal
from all three instances (18). The signal arising from the unenhanced background tissue
can be suppressed by scanning pre and post agent administration, however this of course
requires two imaging scans and enough time for the agent to distribute and accumulate in
vivo. Unfortunately, it becomes highly problematic when trying to distinguish targeted
from non-targeted contrast agents since even with the high relaxivity enhancement in the
targeted complex, the signals arising from both cases are indistinguishable.

It is

understandable that combining the advantages of MRI, which provides high-resolution
anatomical images, with molecular sensitivity within a single imaging system would
greatly aid and possibly simplify the process of detection of diseases. This was the basic
premise of the dreMR: by exploiting the relaxivity magnetic field dependence possessed
by only the bound form of the targeted agent, one could suppress both signal arising from
the non-targeted contrast agent and unenhanced biological tissues, and only obtain signal
arising from the targeted contrast agent (4, 27, 28). Novel relaxometry data published by
17

Koenig et. al. (Fig. 1.8), demonstrated the relaxation rate magnetic field dependence for
six tissues in a rat.

Figure 1.8 The relaxation rates of various rat tissues, at 30 , as a function of magnetic
field strength. (Reprinted with permission: Koenig SH, Brown RD, 3rd, Adams D,
Emerson D, Harrison CG. Magnetic field dependence of 1/T1 of protons in tissue.
Investigative Radiology. 1984;19(2):76-81) (29).

At lower magnetic field strengths, there is a large variation in the relaxation rate
magnetic field dependence; however the relaxivities for all tissues begin to converge as
the magnetic field strength increases above 0.1 T, minimizing the field dependence. A
more important observation is that as the magnetic field strength approaches clinical field
strength (>1 T), the change in

,

, approaches zero for all tissues. Comparing the

strong relaxivity magnetic field dependence of the targeted contrast with the minimal
dependence of non-targeted contrast agents and unenhanced biological tissues, it becomes
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apparent that signal arising only from the bound form of the targeted agent can be
discriminated by modulating the magnetic field within a clinical MRI scanner.

1.3.3 Field Strength, B0, and Temperature Dependence
The relaxivity field dependence is an essential parameter to consider during the
development and optimization of contrast agents, whether they are non-specific or
targeted.

Longitudinal and transverse relaxivities are strongly field dependent over

limited ranges. As the applied magnetic field increases, the field dependence decreases
for longitudinal relaxivity since the relaxation rates of the contrast agent and solvent
converge (observation is reversed for transverse relaxivity) (1, 6, 14, 29). With the
general trend towards higher fields in MRI, (3 T and beyond), to increase both sensitivity
and resolution, the commensurate decrease in agent relaxivity reduces much of the
potential gains (11, 29). An increase in field strength would also amount to an increase in
tissue relaxation rates, suggesting contrast between normal and abnormal tissue will be
field dependent as well (29). Water exchange rate, rotational diffusion, and correlation
time, parameters governing relaxivity, are all temperature dependent, all increasing with
temperature (1, 14, 17). It becomes necessary to understand the parameters governing
both the relaxivity and relaxation times field dependence of the contrast agents and
tissues to choose an optimal field for imaging, factors that impact whether the contrast
agent will become clinically relevant (1, 6, 11, 14, 17, 29).
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1.4 Field-Cycling Relaxometry
Conventional MRI uses a high-field superconducting magnet to both polarize and
image (with the use of gradients systems and RF coils) the nuclei of an object, producing
contrast from the relaxation properties (exploited by pulse sequences) of tissues. A fieldcycling relaxometer directly measures the relaxation rates of samples by modulating the
strength of the magnetic field during a series of magnetization evolution periods (30-32).
The basic premise of ﬁeld-cycling magnetic resonance is the ability to rapidly switch
between magnetic strengths for relaxation and signal acquisition levels during the pulse
sequence without causing artifacts or image degradation due to the fast switching for
acquisition (30). Field-cycling of the magnetic field permits acquisition at one field
strength so that a series of relaxation measurements at different field strengths can be
obtained at a single acquisition field without re-tuning the NMR probe. The acquisition
field is chosen predominantly to maximize signal strength.
As depicted in the general pulse sequence (Fig. 1.9), the sequence consists of three
periods for which the magnetic field is switched and varied: the polarization (
relaxation ( ), and the detection (

), the

) fields. The initial polarization field serves to

increase the Boltzmann nuclear magnetisation of the spin system, the relaxation field
serves to allow the spin system evolve for a specified duration and relax, and finally the
detection field serves to detect the resulting FID signal. An extended recycle delay is
implemented to allow the resistive magnet system to rest before the next cycle,
establishing a thermal equilibrium for magnet and power supply.
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Continuing the

sequence for a series of relaxation field strengths, one can generate a nuclear magnetic
resonance dispersion curve for the relaxation times of the sample.

Figure 1.9 Typical field-cycling relaxometry pulse sequence (Adapted from Kimmich et
al., 2004). The recycle delay (zero field) has been omitted.
The preferred technique for field-cycling relaxometry consists of studying the field
dependence of relaxation times (or rates). Studies employing the field-cycling technique
have been regularly used to measure material properties, contrast agents and fluid
interfaces, and biochemical interactions (32, 33).

The evolution towards medical

applications was predicated on the field dependence of normal and abnormal tissues,
greatest at low field strength (< 0.4 T), ranging from 1 μT to 1.5 T (29, 31, 33-36).
Relaxometry studies have shown field dependencies of various tissue diseased states,
most notably of interest, Parkinson’s and human brain cancers (29, 36-38). Applying
field-cycling techniques to imaging would expand the ability to derive contrast from
normal and abnormal tissues.
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1.4.1 Field Cycling Magnetic Resonance Imaging
Conventional MRI is a multi-parameter imaging method that requires a stable,
constant, homogenous magnetic field throughout the imaging process. Field-cycling MRI
combines the techniques of field-cycling relaxometry with the imaging methods of MRI,
offering access to biological information not available from conventional clinical imaging
(39). Field-cycling MRI uses pulse sequences that differ from conventional MRI. During
field-cycling MRI sequences, the magnetic field strength is modulated several times
before signal detection by varying the current flowing through a resistive magnet that is
inserted into the MRI bore or resistive-permanent magnet hybrid (33, 39). In this manner,
the spin system evolves and relaxes at different relaxation fields to exploit the relaxivity
field dependence, before returning to the scanner’s usual field strength for signal
detection. Field-cycling MRI alludes to measuring biophysical parameters by decoupling
different contrast mechanisms (relaxation times) contributing to the MR signal (40-43).
By exploiting the disparate magnetic field dependence of relaxivity for targeted contrast
agents and unenhanced biological tissues with dreMR, new biophysical contrast
parameters can be measured. Assessment of tumors, liver disease, and disorders of the
brain, kidney, spleen, and pancreas would beneﬁt from the quantitative measurements of
field-cycling relaxometry and imaging (29, 32, 40, 42). The trade-off of field-cycling
imaging over conventional MR imaging involves compromises such as increased imaging
time, decreased spatial resolution and image quality regulated by reduced SNR.
Implementation of this method has several technical challenges, which were investigated
as part of this research.

Interactions between the clinical and field-cycling magnet

systems can lead to image artefacts resulting in misinterpretation of the biophysical
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parameters (33, 34, 42). Careful construction of the field-cycling insert magnet including
an accurately designed active magnetic shield and computer-controlled eddy current
compensation has eliminated to a large extent almost all artefacts. With these technical
challenges under control, this novel imaging contrast has been investigated to optimize
various system and imaging parameters for comparison with conventional MR imaging.
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1.5 Thesis Objectives and Overview
The work present in the thesis was completed by me in the Imaging Research
Laboratories of the Robarts Research Institute under the supervision of Dr. Timothy
Scholl as a Master’s candidate in the Department of Medical Biophysics at Western
University. This research involved a collaboration between the groups led by Dr. Scholl
and Dr. Blaine Chronik in the Department of Physics and Astronomy at Western
University.

This included substantial assistance from Dr. Francisco Martínez-

Santiesteban (Scholl Group), Dr. William Handler (Chronik Group) and graduate student
Mr. Chad Harris (Chronik Group). Many of the original ideas, which form the basis of
dreMR were developed by Dr. Jamu Alford, a former Chronik graduate student and Dr.
Brian Rutt (formerly at the Robarts Research Institute, presently at Stanford University). I
also wish to acknowledge the input of Dr. Peter Caravan (Harvard University) who was
the original developer of Ablavar and his research assistant, Dr. Christian Farrar, who
have provided many helpful discussions. The overall goal of this project was to use Delta
Relaxation Enhanced Magnetic Imaging to assess the albumin uptake in tumours in
clinically relevant murine cancer models using the targeting MRI contrast agent Ablavar.
Specific objectives included:
1) Use of field-cycling relaxometry techniques to measure and characterize the
relaxivity of Ablavar
2) Application and integration of the new dreMR hardware and pulse sequence for
dreMR imaging
3) Examination of Albavar-albumin binding using dreMR imaging to distinguish
only the targeted form of the contrast agent.
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Chapter 2 discusses the development and application of the field-cycling
relaxometry techniques to measure the relaxivity of Ablavar, the implementation of the
new dreMR hardware, pulse sequences, and the integration with the clinical MRI scanner.
Chapter 3 presents the experimental findings and the resulting dreMR images from the
single inversion and double inversion pulse sequence using both phantoms and in vivo
murine cancer models. Chapter 4 summarizes the key experimental findings and the
significance and implications of dreMR imaging.

Current limitations and future

directions to improve dreMR imaging are also discussed.
The samples for Ablavar-albumin relaxation rates measurements were prepared by
me. Their measurements and relaxivity data analysis were completed by me and Dr.
Martínez-Santiesteban, with guidance from Dr. Scholl. The relaxivity modeling using the
Lauffer Model of Relaxivity was provided by Dr. Scholl. Dr. Alford and Mr. Chad Harris
provided the electromagnetic simulation models for the dreMR insert coil and the active
shield. The construction of the dreMR insert coil was completed by Mr. Frank Van Sas
and Mr. Brian Dalrymple under the supervision of Drs. Scholl and Handler. Mr. Harris
and I provided assistance during the construction process. The National Instruments
control software was provided by Dr. Handler. The modified Triple Inversion Recovery
MRI pulse sequence was provided by Dr. Jeff Stainsby (GE Healthcare). The solid state
switch box was previously built by Dr. Alford and Mr. Doug Hie (Physics and Astronomy
Electronics Shop). The gradient amplifier was installed and matched to the dreMR coil
by Joseph Venditto (Performance Controls Incorporated). I built the RF birdcage coil
with assistance and feedback from Patrick Lim. The breast and prostate cancer models
were provided by Dr. Paula Foster and her students Ms. Vasiliki Economopoulos and Ms.
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Christiane Mallett. I was responsible for animal preparations during the in vivo dreMR
studies, with assistance from Dr. Emeline Ribot for the mouse tail-vain catheter. The
water heated mouse anaesthesia bed was designed by Dr. Scholl, and built by Misters Van
Sas and Dalrymple.

Drs. Scholl, Handler, Martínez-Santiesteban, Mr. Harris, and I

participated in the imaging sessions and image analysis. The phantom and in vivo dreMR
images were processed and analyzed by me. Finally, Dr. Scholl, as principal author’s
supervisor, provided guidance and mentorship, helped determine the overall thesis
objectives, reviewed project results, and provided editorial assistance with the thesis
manuscript.
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Chapter 2
Construction, Design and Methods for dreMR
Experiments
The ability to prepare and derive image contrast related to the concentration of
only the bound targeted contrast agent requires additional specialized hardware that must
be added to a clinical superconducting MRI system. For ordinary magnetic resonance
imaging, contrast enhancement is achieved using pulse sequence parameters and contrast
agents that take advantage of the relaxation properties of the tissues of interest. This
process unfortunately suffers from competing signal arising from unenhanced tissues and
enhanced tissue from the contrast agent in its targeted and non-targeted states.

To

identify the image contrast from only the targeted agent, one would be required to scan
pre and post contrast agent administration. This method does not discriminate between
tissues enhanced by bound or unbound contrast agent; however with dreMR imaging,
contrast agents bound to their target can be directly imaged eliminating the need for
baseline imaging. dreMR imaging uses field-cycling MR techniques to modulate the
strength of the main clinical magnetic field to produce the contrast enhancement only
from the targeted form of the contrast agent. The dreMR method can be simply described
as a actively shielded

insert coil within an unmodified clinical superconducting MR

system, controlled by additional supportive hardware and software to prepare sample
magnetization for standard MR imaging. For this purpose, a redesigned 2nd-generation
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dreMR coil was constructed specifically for small animal imaging (mouse-sized), to
include improvements in mechanical, electrical and thermal design (44, 45).
Chapter 2 forms the basis of the design, construction and hardware improvements
to the dreMR insert coil and the supplemental hardware and software. The fundamentals
of the dreMR coil are described, as well as the required hardware and software sequences
to perform dreMR imaging. The supplemental hardware and software include the fast
current switch box to isolate the dreMR coil from the MR scanner during image
acquisition, the power amplifier to drive the dreMR coil, the control systems hardware
and software for integration and synchronization with the MR scanner, the RF coil, and
the modified Triple Inversion pulse sequence with the dreMR magnetic field shifting
preparation stages. All of the equipment was tested offline (outside the MR scanner
room) before integration with the scanner to insure proper operation and to protect
personnel and equipment. Preparations for the phantom and animal models are discussed,
as well as the MRI acquisition and the image processing required to produce the dreMR
images. The field-cycling relaxometry measurements and preparations of the Albavaralbumin concentrations is presented, including the Lauffer Model of Relaxivity, to
demonstrate how the dreMR contrast is derived from the relaxivity magnetic field
dependence of the Albavar-albumin complex.

2.1 Improvements to dreMR B0 Insert Coil and Hardware
In its fundamental form, the dreMR insert coil must produce nearly uniform field
shifts (> 0.1 T) within milliseconds without disrupting the stability of the host scanner
and withstand the potential torques and forces as a result of Lorentz forces. To produce
the desired uniform magnetic field shifts and minimize coupling interactions with the host
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MRI scanner, the auxiliary insert coil needed to observe specific design criteria,
specifically force and torque balancing, magnetic field homogeneity, inductance and
ramping timings, heat dissipation through efficient cooling, and perhaps most
importantly, magnetic coupling with the host MRI scanner.

2.1.1 dreMR B0 Insert Coil
The dreMR insert coil is not directly involved in the process of imaging the
sample, but rather acts to specially prepare sample magnetization before imaging with the
host MRI scanner. The dreMR insert coil produces magnetic field shifts for tissue
magnetization and then is turned off during signal acquisition.

As a result, the

homogeneity requirement for dreMR is much less than for the clinical magnet. Field
calculations based on the electromagnetic designs indicate that inhomogeneity over a 20mm-diameter, 40-mm-long-cylinder is 1.5% (approximate imaging volume of a mouse).
This limited inhomogeneity has only a very limited affect on dreMR contrast producing
an unnoticeable shading.
The requirement to repetitively ramp the magnetic field (on the order of
milliseconds) on and off has the potential to produce eddy-currents capable of inducing
instabilities in the main field that persist throughout signal acquisition, most notably
phase and slice select artefacts. The dreMR insert coil was composed of two concentric
electromagnets, a small solenoid primary coil for producing the magnetic field shifts and
a counter-wound shield coil to largely eliminate the insert’s fringe fields and coupling
with the host MRI scanner.
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Previous design calculations, methods, materials, and constructions techniques
have been described (44, 46, 47); however, efforts have been made to improve the
construction of the active shield for this newest device (45).

There were inherent

practical errors related to methods of construction and winding for the first-generation
dreMR insert coil, such that the final constructed coil deviated from the original
theoretical design. For example, subtle twisting of the magnet windings for the primary
solenoid causing positional variations in both the longitudinal and radial wire locations
compared with the ideal electrical design. This, in turn led to an accumulation of these
small variances eventually causing a net misplacement of the entire coil on the former
bobbin. The construction protocol was adapted to minimize the inherent winding errors
and create a more realistic model of the primary coil.

During winding, a wire

“straightener” was used to remove small bends from the square hollow copper wire (5mm width, 3-mm hole diameter) prior to winding onto a cylindrical G-10 former to create
the primary coil (6 radial layers, 30 wire turns per layer, 15 turns per half, inner diameter
of 8 cm, and length of 17 cm) (45). In addition, the actual positions of each individual
wire loop were measured at each solenoid layer and used in a final design of the active
shield. (45). The resulting single-layer shield wire pattern was counter-wound onto a
second cylindrical G-10 former with diameter and total length of 28.8 cm and 30.5 cm
respectively.
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Figure 2.1 dreMR insert coil. Top row: Left: Schematic drawing of the dreMR coil
(provided by Dr. Scholl). Middle: Winding process of dreMR insert coil with wire
straightening apparatus. Right: Misalignment of wire patterns (top) from original
winding construction protocol, and example of measurement of wire positions after one
winding layer of the primary coil (bottom). Bottom Row: dreMR coil on the patient bed
inside MR scanner. The RF coil and water-heated mouse anaesthesia bed are placed in
front of the dreMR coil to show their integration.
Estimates of improved shielding due to the inclusion of measured wire positions
for accurate calculation of the active shield geometry suggest gains in shield effectiveness
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of better than 15%.

Specifications for the second-generation dreMR B0 insert coil,

designed for mouse imaging include a cylindrical imaging region approximately 5-cm
long and 2.5-cm in diameter. Physical parameters are: 42-cm length, 8-cm inner diameter,
32-cm outer diameter and 50-kg mass.

Electrical parameters include 1.46-mH

inductance, 96.4-mΩ resistance and 0.8697-mT/A magnetic field efficiency (44, 45).

2.1.2 Gradient Amplifier and Control
The shielded dreMR

insert coil was powered by a QDCM 700 series gradient

amplifier (Performance Control Inc., PA, USA). The internal feedback circuit of the
gradient amplifier was calibrated to match the inductance (1.46 mH) and resistance (96.4
mΩ) of the dreMR insert coil, ensuring the gradient amplifiers faithfully reproduced the
input waveforms generated by the National Instruments control hardware (NI DAQ). The
NI DAQ was controlled by custom software written in LabView (National Instruments,
version 11.0) running on a separate laptop computer.

Waveform synchronization

between the NI DAQ and the MRI console was realized by means of a transistortransistor logic (TTL) trigger generated by the MRI system electronics initiated by the
modified pulse sequence. The gradient amplifier and NI DAQ were housed in the MRI
electronics equipment room, and communication between the NI laptop software and NI
DAQ were performed via a 20-m long unshielded fiber-optic Universal Serial Bus (USB)
cable to limit potential electromagnetic noise.
Notable specifications for the bipolar dual-axis gradient amplifier included peak
output current of 430 A for 20 ms, peak output voltage 725 V, output current 270 A rms
over a 300-s averaging window, 200 A rms for greater than 300 s, and a risetime to
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maximum current of 300 μs. From these specifications, it was possible to reliably
achieve a maximum constant magnetic field shift of 375 mT over a 300 s scan and
maximum slew rate of 400 T/s with the dreMR B0 coil.

Figure 2.2 dreMR gradient amplifier positioned next to MR scanner hardware in the
scanner equipment room.

2.1.3 Current Switch Box
The dreMR field homogeneity (~1.5%) is modest compared to that of the host
scanner. This is not a limitation since the field is nominally zero during the image
acquisition. However, small current offsets or fluctuations from the gradient amplifier
powering the dreMR magnet can cause significant image artefacts due to the high field
efficiency of the magnet system (0.8697 mT/A).

A switch is therefore required to

disconnect the dreMR from the gradient amplifier during image acquisition. The gradient
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amplifier is designed to drive inductive loads. Its control circuitry supplies a current
through the load that is proportional to an input voltage. Even when the input voltage is
nominally zero, small offsets present anywhere along the input chain or in the amplifier
circuitry are sensed and converted to a small output current.

In the absence of a

connected load, this will drive the amplifier outputs to maximum voltage. An auxiliary
load with an inductance that is similar to that of the dreMR electromagnet to prevent
current feedback oscillations must be substituted when the dreMR insert coil is isolated
from the current source. A solid-state fast switch box was used to switch to an auxiliary
“dummy load” (an inductor and power resistor in series chosen to match the electrical
characteristics of the dreMR electromagnet, labeled bypass coil in Fig. 2.4) when the
dreMR insert coil was deactivated during image acquisition. Design and construction of
the fast switch box had previously been described (4) such that either the dreMR insert or
the dummy load was attached to the amplifier at all times to prevent runaway current
oscillations from damaging the amplifier. The switch box circuit contained two custombuilt solid-state sub-switches, each with two 400-A 1200-V insulated gate bipolar
transistors (IGBT) (POWEREX 400HA-24A), biased with an optically-isolated driver
circuit (POWEREX BG2A-NF), and two 300-A 1200-V diodes (POWEREX CS641230).
Bipolar current waveforms were achievable with the two separate IGBT current
pathways.

The high-current diodes prevented reverse current from overloading the

protection diode in the transistors while in their off non-conducting state.

Product

specifications for IGBT and diode specified a continuous maximum peak current was 300
A with a 800-ns switching time for the diode, and a maximum peak current was 800 A
with a 600-ns time for the IGBT. The fast switch box circuitry and dummy solenoid load
were mounted on a 19-inch-wide 1000-W fan-cooled heat sink (TW7-1275-flsx, D6
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Industries, Massachusetts, USA) to prevent overheating. Temporal control of the fast
switching circuitry was achieved with TTL signals from the NI DAQ hardware
synchronized to the pulse sequence.

Figure 2.3 The current switch box disconnects the dreMR from the gradient amplifier
during image acquisition. The switch box switches to an auxiliary load when the dreMR
insert coil is deactivated during image acquisition to remove any offset currents and
noise. Right: Picture of the current switch box. Left: Schematic of the integration of the
current switch box with the gradient amplifier, dreMR coil and bypass coil (Adapted from
Alford., 2009).

2.1.4 Radiofrequency Coil
A custom highpass, capacitively-matched, cylindrical eight-rung birdcage RF
coil was built for the second-generation dreMR insert coil. The RF coil was to tuned to
the proton Lamor frequency at 1.5 T (63.86 MHz) with an imaging volume of 5 cm. The
RF coil was shielded with a 150-μm stainless steel mesh cylindrical shield to reduce noise
and coupling with the dreMR insert coil. The RF coil was securely attached with an
extended arm screwed into the exterior of the dreMR insert coil to prevent RF coil
movement during the magnetic field shifting produced by the dreMR insert coil. The
same RF coil was used throughout all phantom and in vivo imaging sessions.
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2.2 dreMR Integration with Scanner
The dreMR imaging method requires custom software to implement the field
shifting required to exploit the relaxivity field dependence of the targeted contrast agents
and tissues. The dreMR pulse sequence consists of two parts: a preparatory stage, and an
imaging stage. The dreMR insert coil was activated during the preparatory stage to
provide the required field shift for magnetization of the spin systems and then deactivated
during the imaging stage. Precise synchronization of the dreMR insert coil and MRI
console was an integral component to acquire meaningful contrast and images that were
free of artefacts. The dreMR insert coil was controlled by a NI DAQ system executing
custom software in LabView (National Instruments Corp. USA) by a separate laptop
computer in the MRI console station. The custom software is summarized in section
2.2.1. Synchronization was achieved by a TTL trigger generated by the MRI system
electronics during the pulse sequence.

2.2.1 Pulse Sequence
The dreMR pulse sequence was based on a standard imaging sequence known as
the Triple Inversion Recovery, controlled by the Blood Suppression imaging option, on a
GE Healthcare 1.5 T CVMR scanner (WI, USA). The Triple Inversion Recovery pulse
sequence contains user-specified delays between the 90o and 180o RF pulses for fatwater-blood suppression. The RF timing delays were leveraged to insert the preparatory
stage required for the dreMR field shifting of B0, which under normal imaging situations
would be held at the native field strength of the scanner. In total, the dreMR pulse
sequence contained the preparatory stage required for the dreMR field shifting (including
TTL output signals for hardware synchronization) followed by an imaging stage for
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acquisition. The imaging sequence used was a Fast Spin Echo XL (FSE-XL). The
preparatory sequence is identical to what is played out in double/triple IR-prepared FSE
scans for black blood imaging of the heart. The preparation stage included options such
that the RF pulses could be suppressed when not required and the time duration of the
field-shifting portion could be optimized. The preparation stage was capable of including
either one or two dreMR field shifts that could be separately specified for pulse duration
and amplitude. The dreMR pulse sequence is generalized in figure 2.2. The simplest
implementation of the dreMR pulse sequence included application of a 90° RF pulse,
followed by a single dreMR field shift (either negative or positive) and then standard
image acquisition (designated: 90°-[Field Shift]-[Acquire]). The single field shift encode
also supported a 90°-180°-[Field Shift]-[Acquire] scheme.

A new double field shift

encode, also known as the dreMR double inversion recovery (4), was developed using a
90°-180°-[positive Field Shift]-180°-[negative Field Shift]-[Acquire] scheme, integrating
both the positive and negative field shifts as part of the same preparation phase of the
pulse sequence. The first 90° pulse in the preparatory stage is a hard pulse, whereas the
180° RF pulses are adiabatic.

Figure 2.4 General dreMR pulse sequence diagram. LEFT: Single shift encode sequence.
The
field shifts support both positive and negative field shifts. RIGHT: The double
field shift encode sequence (DIR).
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2.2.2 Preparatory pulse
The preparatory stage of the dreMR sequence contains a number of necessary
sequence parameters to completely specify either a single or double field shift encode.
Different parameters are either activated or suppressed to achieve the desired preparatory
sequence. The sequence provides user control for the time durations between the 90 °180° RF pulses, the 180°-180° RF pulses, the 90° (or 180°) RF pulse to image acquisition,
the time durations of the field shifts, and tunable delays between the RF pulses and field
shifts. The dreMR preparatory stage (Fig 2.5) is reduced to six important variables: the
P1 time, the P2 time, the P3 time, the delay before the TTL turns on, and the positive and
negative field shift durations. These parameters correspond to the times indicated on
figure 2.3. The parameters are paramount to ensuring that not only does the preparatory
stage provide the desired field shift, but that there are no timing overlaps between the
preparatory stage and imaging stage. For clarification, the P1 time is the time from the
start of the first RF pulse to the middle of the second RF pulse, P2 time is the time from
the middle of the second RF pulse to the middle of the third RF pulse, and the P3 time is
the time from the middle of the third RF pulse to the start of normal FSE acquisition.
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Figure 2.5 A detailed view of the preparation stage. P1, P2 and P3 times are graphically
defined on the timeline.

To achieve a single encode field shift dreMR pulse sequence, both the 180 ° RF inversion
pulses and P3 time are suppressed such that the preparatory stage only consists of the P1
and P2 time durations with a positive or negative field shift (90°-[Field Shift]-[Acquire]).
To achieve a double shift encode field shift dreMR pulse sequence, the entire preparatory
sequence would be played out (Fig. 2.5).

2.3 Analysis of dreMR Contrast
Contrast derived from dreMR imaging, colloquially referred to as dreMR contrast,
produces biophysical information not readily present with standard MRI techniques.
dreMR imaging produces image contrast related to the magnetic field dependence of
relaxation for a biological sample. The contrast is obtained due to the relative lack of
relaxation rate,

, field dependence from unenhanced tissues and tissues enhanced by

non-targeted contrast agents (29, 32, 40, 48). Taking advantage of the intrinsic lack of
dispersion of the unenhanced tissues and non-targeted contrast agents, dreMR imaging
produces contrast arising only from signal enhancement of tissues by only the bound form
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of targeted contrast agents (4, 28, 49). The relaxivity magnetic field dependence of the
targeted form of contrast agent is measureable by manipulating the magnetic field
strength of the MRI system during the preparatory stage of the pulse sequence prior to
signal acquisition. It is therefore the change in
strength,

with respect to the magnetic field

, that is important for dreMR contrast (Equations 2.1-2.4). Given that

(2.1)

the partial derivative of

with respect to the magnetic field,

is simply

(2.2)

This relationship can be further simplified by the observation that
)

(2.3)

an approximation that is supported by literature (1, 8-10, 14, 29, 31, 48) and results
acquired from field-cycling relaxometry data. This results in a very simple relationship
relating the change in

with respect to the magnetic field strength, contrast agent

concentration and the magnetic field dependence of contrast agent relaxivity:

(2.4)

There are two approaches to producing dreMR contrast. The simplest method
involves the weighted subtraction of two
magnetic field shifts, one with a positive (

-weighted images with different dreMR
) and the other with a negative (

)

magnetic field shift during the preparatory stage of the pulse sequence (27). Subtraction
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of the T1+ and T1- images would produce an image where the intensity would be due to the
magnetic field dependence of the biological tissues and administered targeted contrast
agent.
A simplified derivation of the dreMR subtraction method is summarized below.
The derivation assumes the pulse sequence starts with a saturation radiofrequency pulse
to eliminate pre-existing longitudinal magnetization followed by a
The effect of finite ramping times for the

preparatory pulse.

preparation pulse (i.e. effective offset field,

∆Beff) is ignored since the ramping times (~ 1-2 ms) are significantly less than the
duration of the pulse (~ 300 ms). Application of the field-shifting pulse has two effects, it
modulates the steady state longitudinal magnetization and it changes the relaxation rate,
of the sample. The steady-state longitudinal magnetization is proportional to the
amplitude of the sum of the field-shifting and clinical magnetic fields. The application of
a

preparation pulse scales

strength) by a factor of

(the longitudinal magnetization at the clinical field
, effectively increasing the magnetization for a

positive preparatory pulse and decreasing it for the negative preparatory pulse. The
longitudinal magnetization,
duration,

, available for imaging after a preparatory pulse

of

, is therefore
(2.5)

where

is the relaxation rate for the sample at a magnetic field strength of

.

The resulting image intensity of a positive or negative magnetic dreMR field shift
is determined by extrinsic MR hardware, software and the readout sequence. A scaling
factor, , can be included to account for the intrinsic and extrinsic factors (proton density,
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radiofrequency coil homogeneity, transverse relaxation time, etc.), therefore the final
image intensity would be the product of the scaling factor and
(2.7)
The dreMR subtraction methods takes the normalized difference of field-shifted images,
and

.

This normalization removes the influences of the changing equilibrium

magnetization described above.
(2.8)
(2.9)
If the assumption is made that
approximate

is constant in the vicinity

, it is possible to

for the resulting image intensity. This assumption is only

valid for specific contrast agents exhibiting a constant
of the dreMR magnetic field shifts (

within the imaging region

.
, assuming a constant

(2.10)
(2.11)
]

(2.12)
(2.13)

The equation quantifies the dreMR contrast intensity in a particular voxel after
subtraction in terms of physical parameters such as

,

, and the change in

. The

hyperbolic sine term accounts for the characteristic contrast produced by the dreMR
method. The exponential decay function accounts for the inherent loss of contrast that
occurs when the longitudinal relaxation time is set too long such that the voxel
magnetizations of the images begin to saturate.
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The second method involves a single T1-weighted sequence referred to as Double
Inversion Recovery (DIR) dreMR pulse sequence (dreMR-DIR) (see Fig. 2.2). Similar to
conventional inversion recovery sequences, where signal intensities from tissue with
specific relaxation rates are suppressed based on inversion times, the dreMR-DIR pulse
sequence suppresses signals arising from tissues without a relaxation rate magnetic field
dependence,

(4). During the preparatory stage of the pulse sequence, two field-

shifting pulses and two RF 180° inversion pulses are applied to maximize the image
contrast for dependence of

and minimize it for dependence of

at the end of

the preparatory stage of the pulse sequence (start of the imaging sequence). The dreMRDIR sequence therefore directly measures the relaxation rate magnetic field dependence
and does not required any image post processing.

2.4 Phantom Preparation
MRI phantoms (Fig. 2.6) were prepared for analysis using the dreMR pulse
sequences. The samples contained various concentrations of Ablavar and rabbit serum
albumin and were all dissolved in 1× phosphate buffer saline (PBS), pH of 7.4 (KH2PO4
1.06 mM, NaCl 155.17 mM, Na2HPO4-7H2O 2.97 mM) (Product Code 10010023, Gibco,
Invitrogen, Burlington, ON, Canada). The rabbit serum albumin (RSA) was purchased as
a lyophilized powder, essentially globulin free (~99 %) (Sigma-Aldrich, lot
#117K7565V, agarose gel electrophoresis).
The phantom (Fig. 2.6) was prepared in a grid-like fashion with various sample
concentrations of RSA and Ablavar. Samples from left to right contained increasing
concentrations of RSA dissolved in PBS: 0 μM, 50 μM, 100 μM, 350 μM, and 700 μM.
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Samples from top to bottom contained increasing concentrations of Ablavar dissolved in
PBS: 0 μM, 50 μM, 100 μM, 250 μM, 500 μM, and 1000 μM.

Figure 2.6 The arrangement of samples in the phantom. Samples from left to right
contained increasing concentrations of RSA, ranging from 0 to 700 μM. Samples from
top to bottom contained increasing concentrations of Ablavar, ranging from 0 to 1000
μM.

2.5 Field-Cycling Relaxometry

Figure 2.7 Basic Nonpolarized and Prepolarized sequence. The upper trace shows the
switching of field values between the fixed polarization field ( ), the variable relaxation
field ( ), and the fixed detection field ( ), whereas the bottom trace shows the RF
pulse followed after a small delay by the FID acquisition.
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DreMR contrast is derived from the relaxivity magnetic field dependence of the
bound targeted MR contrast agent. The characteristic high relaxivity magnetic field
dependence of bound paramagnetic contrast agents enables suppression of tissue contrast
from unbound agents and unenhanced tissue, thereby increasing probe specificity.
Ablavar binds specifically to serum albumin and has a strong magnetic field dependence
for serum albumin around 1.5T (1, 8, 19). A sample of 80-μM Albavar dissolved in 4%
w/v RSA was measured and acquired using nuclear magnetic resonance dispersion
(NMRD) data for magnetic field strengths ranging from 0.010 MHz (0.23 mT) to 42.49
MHz (1.0 T), using a SpinMaster FFC2000 1T C/DC (Stelar s.r.l., Italy) fast field-cycling
nuclear magnetic resonance relaxometer.

Typical methods to measure T1-dispersion

profiles (plots of longitudinal relaxation times as a function of field intensity at a constant
temperature) at variable field strengths below 1 T are the prepolarized sequence (PP),
appropriate for low relaxation fields (Br), and the nonpolarized sequence (NP),
appropriate at higher relaxation fields (Fig. 2.5). The pulse sequence comprised of the
NP and PP sequences with a crossover field of 12 MHz (i.e. the relaxation field at which
the sequence switches from NP to PP). The sequences were automated experiments
designed to measure the longitudinal relaxation rate (R1) at a given relaxation field. For
every given

, the FID signal was measured as a function of the time interval tau (τ)

(variable relaxation interval), keeping the other (switching, recycle delay, polarization,
acquisition) times constant. The NP and PP were comprised of the same systematic
setup, the only difference was that the NP sequence had a polarization field set to zero (Bp
= 0). Each sequence block FID acquisition started with a recycle delay set to ten times
the maximum T1 (

, followed by a balancing time of
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– , to balance

thermal dissipation in the magnet. The relaxometer cycled to the polarization field of 30
MHz for a time of

to reach a steady state of magnetization, then cycled to the

relaxation field ( ) for an interval time of τ. The relaxometer finally cycled to the
acquisition field of 16.2 MHz, after which a 90° RF pulse was applied and the FID signal
was acquired. The sequence was repeated for 16 blocks, with a decreasing relaxation
interval (τ), to calculate the relaxation time at the specific relaxation field with an
automated multiblock non-linear, least squares fit. The process was repeated for 30
points (determined by the relaxometer on a logarithmic scale) to complete the T1dispersion profile.
At higher field strengths, an insertable field-cycling relaxometer system (MRIn,
Stelar s.r.l., Italy) was used to acquire NMRD curves for ± 0.25 T field shifts about the
clinical field strengths of 1.5 T. An Inversion Recovery sequence was used, similar to the
PP sequence, except the relaxometer cycled to the acquisition field after the polarization
field and applied a 180 RF pulse before cycling to the relaxation field. The polarization
and acquisition fields of the insertable field-cycling relaxometer were set to zero
corresponding to a Larmor frequency of 63.86 MHz at 1.5T.
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Figure 2.8 NMRD data was acquired using the Spinmaster FFC2000 1T C/DC (Stelar
s.r.l., Italy) and MRIn equipment. NMRD data for magnetic field strengths ranging from
0.010 MHz to 42.49 MHz was acquired using the SpinMaster relaxometer (Top Left).
Top Right and Bottom Row: The insertable field-cycling relaxometer system (MRIn,
Stelar s.r.l., Italy) used to acquire NMRD curves for ± 0.25 T field shifts about the
clinical field strengths of 1.5 T (Top Right and Bottom Row).

The relaxation rates for the contrast agent solution of 80 μM Albavar dissolved in
4% w/v RSA was measured and acquired (
(

) and the plain buffer solvent

) were recorded for computing the relaxivity ( ) of the contrast agent,
(2.14)

where [CA] represents the concentration of the contrast agent sample on a per gadolinium
ion basis. The estimated R1 error interval was 2% or less. Samples were maintained at
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for all measurements using heated air.
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Longitudinal relaxation was modeled using a modification of the SolomonBloembergen-Morgan theory formulated by R. Lauffer (9). Contributions to spin-lattice
relaxation from the inner hydration sphere were calculated as:
(2.15)

where

was the spin-lattice relaxation rate due to inner-sphere interactions, [M]

was the molar concentration of the paramagnetic species, [H2O] was the molar
concentration of water, qIS was the inner-sphere hydration number, T1M was the relaxation
time for bound inner-sphere water molecules, and τm was the water residency time.
The inner sphere spin-lattice relaxation rate, including dipolar and contact
interactions, was estimated using:

(2.15)
where

was the magnetic permeability of vacuum,

protons,
ion,

was the electronic g-factor,

was the Bohr Magneton,

was the gyromagnetic ratio for

was the total electronic spin for the metal

was the metal ion-proton separation and

electron-nuclear hyperfine coupling constant.

and

was the

were the proton and electron

Larmor precessional frequencies (rad/s) in the applied magnetic field respectively.
The dipole-dipole correlation time,
electronic spin relaxation time,
correlation time,

, was calculated from the longitudinal

, the water residency time,

and the rotational

, as follows:
.
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(2.16)

The longitudinal electronic spin relaxation rate is parameterized as:
where
Finally, the scalar relaxation time,

.

(2.17)

, was determined by:
.

(2.18)

2.6 Animal Preparation
The animal experiments were approved by the Animal Use Subcommittee of the
University Council on Animal Care at The University of Western Ontario following the
guidelines of the Canadian Council on Animal Care (protocol number 2010-210 and
2011-085) (Appendix B and C).
A total of three mice were used, all following the same preparation, anesthesia,
and injection protocols for imaging. Two cancer model mice were used for the dreMR
subtraction method, and one healthy mouse was used for the dreMR-DIR method.
The mice were initially anesthetized with 5% Isoflurane (Baxter Corporation,
Mississauga, ON, Canada) with a vaporizer (VetEquip, Pleasanton, CA, USA) in an
induction chamber. The mice were fitted with a breathing rate monitor (Small Animal
Instruments Inc., Stony Brook, NY, USA) to monitor the breathing rates under anesthesia
and then transferred to a custom water-heated mouse bed where Isoflurane was
administered (reduced to 2% with O2) through a nose cone. The Isoflurane concentration
was adjusted between 1-3% during the imaging session based on breathing rate. The
water temperature of the mouse bed was controlled to body temperature with a T/Pump
(Gaymar, Torrington, CT, USA). The mice were injected by tail-vein with a bolus of
Ablavar diluted in saline at a dose of 100 μM/kg. The two cancer model mice were
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sacrificed using Euthanyl Forte (Pentobarbital Sodium Injection) at a dose of 2 mL/kg
(Bimeda-MTC Animal Health Inc, Cambridge, ON, Canada).

2.6.1 Prostate Cancer model
PC-3M cells (NCI, Frederick, MD, USA) were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Burlington, ON,
Canada). All cells were maintained at 37

and 5% CO. Two million PC-3M cells

suspended in 100 μL Hank's Balanced Salt Solution (HBSS) (Gibco, Invitrogen,
Burlington, ON, Canada) were injected subcutaneously in the right and left ﬂanks of a
female (19 g) nude mouse (nu/nu; Charles River Laboratories, QC, Canada) at day 0 (50).
The mouse was imaged on day 28.

2.6.2 Breast Cancer model
MDA-MB-231 cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% FBS.
maintained at 37

All cells were

and 5% CO. One million MDA-MB-231 cells suspended in 50-μL

HBSS were injected into the mammary fat pad on the left side of a female (18 g) nude
mouse (nu/nu; Charles River Laboratories, QC, Canada) at day 0. The mouse was
imaged on day 29.

2.7 Magnetic Resonance Acquisition and Image Processing
The dreMR pulse sequence was a custom-built sequence based on a standard
imaging sequence known as the Triple Inversion Recovery. The pulse sequence consisted
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of a preparatory stage, whereby the
imaging acquisition. The

magnetic field shifts were applied, followed by

magnetic field shifts were applied for each row of k-space

and were timed to end 2 ms prior to image acquisition. The dreMR subtraction method
takes the normalized difference of the field-shifted images: positive field shifted images
(

, and negative field shifted images (

perform the image processing.

. The raw data for all images were acquired to

The data sets were first normalized (to remove the

influences of the changing equilibrium magnetization) and scaled (if there were multiple
images were taken). A subtraction-based pixel by pixel phase correction was then applied
to minimize the effects phase shifts induced by the eddy currents. The phase difference
of the k-space data from the
data sets (either

or

and

data sets was calculated and applied to one of the

). A complex subtraction of the

before obtaining the final magnitude dreMR image.

and

data sets calculated

The double inversion recovery

dreMR sequence required no image processing. All the image processing was performed
using Matlab 2012 tools (MathWorks, Natick, Massachusetts, U.S.A.)

2.8 Magnetic Resonance Imaging
2.8.1 Phantoms
The fast spin-echo pulse sequence parameters used to produce the dreMR images
using the dreMR subtraction method were: 1000-ms pulse repetition time, 12.08-ms echo
time, echo train length of two, 122 Hz per pixel, one average, isotropic in-plane resolution
of 0.27 mm, and 15-mm slice thickness. The matrix size was 256256.. The main
magnetic field was modulated ±0.221 T with preparatory dreMR pulse of 500-ms
duration. The ΔB pulses were timed to end 2 ms prior to image acquisition.
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The dreMR-DIR (Double Inversion Recovery) sequence parameters used to
produce the dreMR images using the dreMR DIR method were: : 450-ms pulse repetition
time, 6.904-ms echo time, 50-ms inversion time, echo train length of two, 122 Hz per
pixel, one average, isotropic in-plane resolution of 0.55 mm, and 8-mm slice thickness.
The matrix size was 128128. The main magnetic field was modulated with preparatory
dreMR pulse durations of a 50-ms P1 time, a P2 time of 150 ms with a positive 0.221-T
magnetic field shift, and a P3 time of 50 ms with a negative 0.221-T magnetic field shift.
The ΔB pulses were timed to end 2 ms prior to image acquisition.

2.8.2 In vivo Research
2.8.2.1 Prostate Cancer Model
The fast spin-echo pulse sequence parameters used to produce the axial dreMR
images using the dreMR subtraction method were: 500-ms pulse repetition time, 9.376ms echo time, echo train length of two, 81 Hz per pixel, one average, isotropic in-plane
resolution of 0.39 mm, and 4-mm slice thickness. The matrix size was 128128. The
main magnetic field was modulated ±0.221 T with preparatory dreMR pulses of 300-ms
duration. The ΔB pulses were timed to end 2 ms prior to image acquisition. Nine data
sets were averaged to produce the resulting dreMR image. Two 4-mm-diameter NMR
vials containing 160 μM of Ablavar loaded with and without 4.0% w/v RSA were placed
within the imaging region of the tumours to serve as dreMR contrast controls.

- and

weighted were also obtained before and after Ablavar was injected into the animal.
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2.8.2.2 Breast Cancer Model
The fast spin-echo pulse sequence parameters used to produce the axial dreMR
images using the dreMR subtraction method were: 500-ms pulse repetition time, 9.376ms echo time, echo train length of two, 81 Hz per pixel, one average, isotropic in-plane
resolution of 0.39 mm, and 4-mm slice thickness. The matrix size was 128128 Ten data
sets were averaged to produce the resulting dreMR image. The fast spin-echo pulse
sequence parameters used to produce the coronal dreMR images using the dreMR
subtraction method were: 500-ms pulse repetition time, 8.512-ms echo time, echo train
length of two, 81 Hz per pixel, 10 averages, in-plane resolution of 0.93x0.38 mm, and 4mm slice thickness. The main magnetic field was modulated ±0.221 T with preparatory
dreMR pulses of 300 ms in duration. The ΔB pulses were timed to end 2 ms prior to
image acquisition. Two 4-mm-diameter NMR vials containing 160 μM of Ablavar loaded
with (labeled 2) and without (labeled 1) 4.0% w/v RSA were placed within the imaging
region of the tumours to serve as dreMR contrast controls.

- and

-weighted were also

obtained before and after Ablavar was injected into the animal.

2.8.2.3 Healthy Mouse – DIR sequence
The dreMR-DIR (Double Inversion Recovery) sequence parameters used to
produce the dreMR images using the dreMR DIR method were: 450-ms pulse repetition
time, 6.744-ms echo time, 50-ms inversion time, echo train length of two, 122 Hz per
pixel, five averages, isotropic in-plane resolution of 0.70 mm, and 2-mm slice thickness.
The matrix size was 128128. The main magnetic field was modulated with preparatory
dreMR pulse durations of a 100-ms P1 time, a P2 time of 100 ms with a positive 0.221-T
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magnetic field shift, and a P3 time of 90 ms with a negative 0.221-T magnetic field shift.
The ΔB pulses were timed to end 2 ms prior to image acquisition. Two 4-mm-diameter
NMR vials containing 160 μM of Ablavar loaded with (2) and without (1) 4.0% w/v RSA
were placed within the imaging region of the tumours to serve as dreMR contrast
controls.

-weighted images were obtained, prior to Ablavar injection, to overlay the

dreMR-DIR image.
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Chapter 3
Results
In Chapter 3, the relaxation rates of 80-μM Albavar dissolved in 4% w/v RSA
were measured for magnetic field strengths ranging from 0.010 MHz (0.23 mT) to 42.49
MHz (1.0 T), and an insertable field-cycling relaxometer system was used to acquire
NMRD curves for ± 0.25 T field shifts about the clinical field strengths of 1.5 T. The
relaxometry data analysis demonstrated the basis by which the dreMR contrast is derived
during MR imaging.

dreMR imaging was performed using the single inversion

subtraction method and the double inversion recovery method. Phantoms and in vivo
mouse models were used for both dreMR imaging methods, and the resulting dreMR
contrast images are shown. The appropriate image post-processing are implanted to
correct for the necessary field normalization and phase corrections for the single inversion
subtraction based method.

3.1 Relaxometry Data - Fitting Results Using Lauffer Model of
Relaxivity
dispersion experiments were conducted to measure the field dependence of
NMR spin-lattice relaxation times of 80-μM Ablavar with and without RSA from 10 kHz
to 64 MHz (NMRD profiles) using the SpinMaster FFC2000 1T C/DC and MRIn
relaxometers. The red line (Fig. 3.1 A and B) indicates the imaging region of interest.
dreMR is able to exploit the characteristic high relaxivity magnetic field dependence of
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the bound paramagnetic contrast agent about 1.5 T (63.86 MHz) to produce image
contrast that is proportional to the concentration of the targeted contrast agent. The
significant change in relaxivity between the bound (Fig. 3.1 A) and unbound (Fig. 3.1 B)
contrast agent is noted in the change in scale of the two graphs below.
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Figure 3.1 Fitting Results Using Lauffer Model of Relaxivity for 80-μM sample of
Ablavar measured at 37°C. The Lauffer model for inner-sphere dipole-dipole relaxation
(red trace) has been fit to relaxivities derived from NMRD data at 37°C. (circles) Sample
with 4% w/v Rabbit Serum Albumin. (triangles) No Rabbit Serum Albumin.
Table of Fitting Results
Table 1. Longitudinal relaxation model using a modification of the SolomonBloembergen-Morgan theory formulated by R. Lauffer. The fitted parameters and their
uncertainties (one standard deviation) are given in the following table.
Parameter

Ablavar with RSA
37°C
38.4 ± 4.2
5.72 ± 0.59
552 ± 19
578 ± 50
3*106 (fixed)
0.31 (fixed)
1 (fixed)

Units
ps
ns
ns
ps
rad/s
pm
-

Ablavar
37°C
102.0 ± 14
0.24 ± 0.01
552 (fixed)
154.3 ± 5.9
3*106 (fixed)
0.31 (fixed)
1 (fixed)

: Correlation time for modulation of the transient zero-field splitting, : Rotational correlation
time,
: Water residency time,
: Electronic relaxation time at zero field,
: electronnuclear hyperfine coupling constant,
: metal ion-proton separation,
inner-sphere
hydration number
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3.2 Phantom Images
3.2.1 dreMR Single Inversion subtraction
A phantom study was conducted in which the dreMR single inversion subtraction
method was implemented to produce a dreMR image. The method required the weighted
subtraction of two
with a positive (

-weighted images with ±0.221 T dreMR magnetic field shifts, one
) and the other with a negative (

) magnetic field shift during the

preparatory stage of the pulse sequence. Subtraction of the T1+ and T1- images produce an
image where the contrast intensity was due to the magnetic field dependence of the
targeted contrast agent. Phantoms (Fig. 3.2) were prepared in a grid-like fashion with
various sample concentrations of RSA and Ablavar in order to test the proposed method
without any physiological effects. The resulting dreMR image is presented as a falsecolour image.
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Figure 3.2 Phantom and MRI images. Top: Arrangement of the samples in the phantom.
Samples from left to right contained increasing concentrations of RSA, ranging from 0 to
700 μM. Samples from top to bottom contained increasing concentrations of Ablavar,
ranging from 0 to 1000 μM. Bottom: Subtraction of the -weighted images. Images A
and B show the -weighted images using the dreMR pulse sequence with positive (A)
and negative (B) field shifts of 0.221 T. Image C shows the resulting dreMR image using
the dreMR subtraction method.
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3.2.2 dreMR Double Inversion Recovery
A phantom study was conducted in which the dreMR Double Inversion Recovery
method was implemented to produce a dreMR image. Similar to conventional inversion
recovery sequences, where signal intensities from tissue with specific relaxation rates are
suppressed based on inversion times, the dreMR-DIR pulse sequence suppresses signals
arising from tissues without a relaxation rate magnetic field dependence and therefore
required no image processing. Phantoms (Fig. 3.3 A) were prepared in a grid-like fashion
with various sample concentrations of RSA and Ablavar in order to test the proposed
method without any physiological effects.

A

-weighted image (Fig. 3.3 B) was

acquired using a standard fast spin-echo pulse sequence to observe and measure the
resulting contrast from the dreMR-DIR image (Fig. 3.3 C). The dreMR-DIR image is
presented as a grayscale image to compare with the standard FGRE sequence. The
samples with the lowest concentrations of Ablavar and RSA exhibit limited signal
intensities, while the samples with the larger concentrations of Ablavar and RSA show
increased signal intensities.
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Figure 3.3 Phantom and MRI images. Top: (A) Arrangement of the samples in the
phantom. Samples from bottom to top contained increasing concentrations of RSA,
ranging from 0 to 700 μM. Samples from left to right contained increasing concentrations
of Ablavar, ranging from 0 to 1000 μM. (B) -weighted image using a standard fast
gradient echo pulse sequence acquired at 1.5 T (no field shifting). (C) Image shows the
resulting dreMR image acquired with the dreMR-DIR sequence. The dreMR-DIR
method demonstrates the ability to both suppress and enhance signal intensities of various
albumin concentrations bound to various Ablavar concentrations without any post
processing.
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3.3 In vivo Images
3.3.1 Prostate Cancer Model
An in vivo study was conducted in which the dreMR single inversion subtraction
method was implemented to produce a dreMR image. The method required the weighted
subtraction of two
with a positive (

-weighted images with ±0.221 T dreMR magnetic field shifts, one
) and the other with a negative (

) magnetic field shift during the

preparatory stage of the pulse sequence. Subtraction of the T1+ and T1- images produce an
image where the contrast intensity was due to the magnetic field dependence of the
targeted contrast agent. A female NU/NU mouse was injected with the human prostate
cancer cell line PC-3M and developed tumours on both flanks The mouse was imaged 28
days post PC-3M cell injections. Two 4-mm NMR vials containing 160 μM of Ablavar
loaded with and without 4.0%w/v RSA were placed within the imaging region of the
tumours to serve as dreMR contrast controls. Axial

-weighted images pre- (Fig. 3.4 A)

and post-injection (Fig. 3.4 B) of albumin-targeted gadolinium contrast agent (Ablavar),
and axial

-weighted image (Fig. 3.4 C) post-injection were taken and indicated a

significant tumour volume.

Axial

-weighted subtracted images of post- and pre-

injection of Ablavar (false colour (3.4 D) and grayscale (3.4 E)) were taken to indicate
regions where gadolinium was present. Subtraction of the T1+ and T1- images produced a
dreMR image (Fig. 3.4 F).

Taking advantage of the intrinsic

dispersion of the

unenhanced tissues and non-targeted contrast agents, the dreMR single inversion
subtraction method produced contrast arising only from signal enhancement of tissues by
only the bound form of targeted contrast agent. The resulting dreMR image is presented
as a false-colour image.
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Figure 3.4 Axial image of a female NU/NU mouse under study that developed prostate
cancer tumours on both flanks and imaged 28 days post PC-3M cell injections. Two
4-mm NMR vials containing 160 μM of Ablavar loaded (2) with and (1) without 4.0%
w/v RSA were placed within the imaging region of the tumours to serve as dreMR
contrast controls. Top: (A and B) -weighted images pre- and post-injection of Ablavar.
(C)
-weighted image indicating significant tumour volume. The tumours are
demarcated and indicated with the arrows. Bottom (D and E).
-weighted subtracted
images of post- and pre-injection of Ablavar ((D) and (E)) indicate regions where
gadolinium was present. (F) Resulting dreMR axial image using the dreMR subtraction
method. Notice the dramatic change in contrast from the standard pre- and post-injection
subtracted images compared to the dreMR image. The contrast from the dreMR image
shows only signal intensities arising from the bound form of Ablavar and albumin.
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3.3.2 Breast Cancer Model
An in vivo study was conducted in which the dreMR single inversion subtraction
method was implemented to produce a dreMR image. The method required the weighted
subtraction of two
with a positive (

-weighted images with ±0.221 T dreMR magnetic field shifts, one
) and the other with a negative (

) magnetic field shift during the

preparatory stage of the pulse sequence. Subtraction of the T1+ and T1- images produce an
image where the contrast intensity was due to the magnetic field dependence of the
targeted contrast agent. A female NU/NU mouse was injected with the human breast
cancer cell line MDA-MB-231 and developed a tumour in the mammary fat pad on the
left side. The mouse was imaged 29 days post MDA-MB-231 cell injections. Two 4-mm
NMR vials containing 160 μM of Ablavar loaded with and without 4.0% w/v RSA were
placed within the imaging region of the tumours to serve as dreMR contrast controls.
Axial

-weighted images pre- (Fig. 3.5 A) and post-injection (Fig. 3.5 B) and coronal

(Fig. 3.5 F) of albumin-targeted gadolinium contrast agent (Ablavar), and axial

-

weighted image (Fig. 3.5 C) post-injection were taken and indicated significant a tumour
volume. Subtraction of the T1+ and T1- images pre- (Fig. 3.5 D) and post-injection (Fig.
3.5 E and 3.5 F) of Ablavar produced an axial and coronal dreMR images. Taking
advantage of the intrinsic

dispersion of the unenhanced tissues and non-targeted

contrast agents, the dreMR single inversion subtraction method produced contrast arising
only from signal enhancement of tissues by only the bound form of targeted contrast
agent. The resulting dreMR images are presented as a false-colour image.
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Figure 3.5 Axial and coronal images of a female NU/NU mouse under study that
developed a large breast cancer tumour in the mammary fat pad and imaged 29 days post
MDA-MB-231 cell injections. Two 4-mm NMR vials containing 160 μM of Ablavar
loaded (2) with and (1) without 4.0% w/v RSA were placed within the imaging region of
the tumours to serve as dreMR contrast controls. Top: (A and B) -weighted images
pre- and post-injection of albumin-targeted gadolinium contrast agent (Ablavar). (C) weighted image indicating significant tumour volume. The tumours are demarcated and
indicated with the arrows. Bottom (D and E). Resulting dreMR axial image using the
dreMR subtraction method of (D) pre- and (E) post-injection of Ablavar. (F) -weighted
post-injection coronal images with the tumour demarcated. (G) Resulting dreMR coronal
image using the dreMR subtraction method post-injection of Ablavar. The significant
change in contrast from the dreMR image shows only signal intensities arising from the
bound form of Ablavar and albumin.
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3.3.3 Double Inversion Recovery
An in vivo study was conducted in which the dreMR Double Inversion Recovery
method was implemented to produce a dreMR image. Similar to conventional inversion
recovery sequences, where signal intensities from tissue with specific relaxation rates are
suppressed based on inversion times, the dreMR-DIR pulse sequence suppresses signals
arising from tissues without a relaxation rate magnetic field dependence and therefore
required no image processing. Two 4-mm NMR vials containing 160 μM of Ablavar
loaded with and without 4.0% w/v RSA were placed within the imaging region of the
tumours to serve as dreMR contrast controls. A standard

-weighted image (Fig. 3.6 A)

image using a standard fast gradient echo pulse sequence acquired at 1.5 T (no field
shifting) was taken to overlay the dreMR-DIR image (Fig. 3.6 B). The dreMR-DIR
image was acquired with the magnetic field shifting parameters of 100-ms positive 0.221T magnetic field shift (P2 Time) and 90-ms negative 0.221 T magnetic field shift observe
and measure the resulting dreMR-DIR image (Fig. 3.6 B). The dreMR-DIR image is
presented as a false-colour image overlaid with the standard FGRE
(Fig. 3.6 C).
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-weighted image

Figure 3.6 Direct albumin imaging using the dreMR Double Inversion Recovery (DIR)
pulse sequence. Two 4-mm NMR vials containing 160 μM of Ablavar loaded with and
without 4.0% w/v RSA were placed within the imaging region to serve as dreMR contrast
controls. Top left (A): -weighted image using a standard fast gradient echo pulse
sequence acquired at 1.5 T. Bottom left (B): dreMR-DIR image with 100-ms positive
0.221 T magnetic field shift (P2 Time) and 90-ms negative 0.221 T magnetic field shift.
Right (C): Overlay of dreMR-DIR and -weighted image. The dreMR-DIR method
enables suppression of unbound agents and unenhanced tissues contrast, thereby
increasing agent specificity.
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Chapter 4
Discussion
4.1 Discussion
Delta Relaxation Enhanced magnetic resonance (dreMR) is an imaging method
capable of producing contrast proportional only to the concentration of the bound form of
the targetable contrast agent using a dynamic field-cycling technique. The characteristic
high relaxivity magnetic field dependence of bound paramagnetic contrast agents enables
suppression of unbound agents and unenhanced tissues contrast. The ability to adapt
field-cycling relaxometry to MRI increases its sensitivity to image contrast agents with
molecular targeting characteristics. The effect of removing the magnetic field shifting
pulses during the preparatory phase of the pulse sequence diminishes the ability to
distinguish dreMR contrast arising due to the targeted form of the targetable contrast
agent. Without the magnetic field shifts, the relaxivity magnetization field dependence
cannot be exploited and the contrast would produce a conventional T1-weighted image.
The dreMR single inversion subtraction and double inversion recovery methods both
exploit the relaxivity magnetic field dependence, albeit in different ways.
Using field-cycling relaxometry, it can be seen the relaxation field dependence,
, presents strong evidence of contrast agent binding (Fig. 3.1 A and B), evident by the
relaxivity dispersion. At 1.5 T, the relaxivity of the targeted and non-targeted contrast
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agent with rabbit serum albumin was 16 mM-1s-1 and 7.5 mM-1s-1, which was in
agreement with values reported in literature (1, 12, 19).
The significance is not the relaxivity at a fixed magnetic field strength, but rather
its change with respect to the magnetic field. From the relaxometry data, imaging with
the administration of Ablavar at 1.5 T would result in an absolute relaxivity enhancement
of 2.1 (ratio of targeted Ablavar to non-targeted Ablavar), whereas the relaxivity slope
enhancement ratio was 95 (from 1.25 T to 1.75 T). The large increase of the relaxivity
slope enhancement ratio over the absolute relaxivity enhancement of only the targeted
form of Ablavar (non-enhanced tissues and non-targeted Ablavar do not demonstrate
strong relaxivity field dependences (9, 29)) is what makes dreMR imaging feasible. The
phantom experiments demonstrate magnetization can be prepared and produce signal
intensities proportional to

using both dreMR imaging techniques (single inversion and

double inversion).
The single inversion subtraction dreMR technique required an acquisition of two
images acquired with magnetic field shifts, equal in duration and magnitude. The raw
data from the field-shifted images are then normalized to remove the influences of the
changing equilibrium magnetization through post-processing. Minor inductive coupling
between the dreMR B0 insert coil and the clinical MRI system produce eddy currents in
the conductive materials in the MRI system, even with the use of active shielding. The
eddy currents create a frequency offset such that there became a shift within the field-ofview along the frequency encoding and slice selection directions.

The phase-based

correction was meant to correct only the shift in the frequency encoding direction. Eddy
currents induced by the rapid switching dreMR B0 insert coil reduces the quality of the
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final dreMR image, therefore a phase-based correction was applied to the positive and
negative

-weighted images.

The phase difference from the k-space data from the

positive and negative field variations were minimized to correct for this observation.
After the appropriate field normalizations and phase correction, a complex subtraction of
the complex k-space data was performed before obtaining the final magnitude dreMR
image. The final dreMR images (refer to Figures. 3.4 F and 3.5 E and G) produced by the
subtraction based single inversion dreMR technique produces contrast proportional to

,

where the magnetic field shifts were created by the dreMR B0 field-cycling insert coil.
The penalty for the single inversion subtraction dreMR technique is a drop-off in SNR, a
reduction of approximately 20%, however the gains in probe specificity more than
compensate for this drawback.
Prior to injection of Ablavar, the dreMR image (Fig 3.5 D) produced no tissue
contrast. Post-injection of Ablavar (Fig 3.4 B, Fig. 3.5 B), the T1-weighted images
showed an increase in contrast associated with accumulation of Ablavar, however the
ability to distinguish contrast arising from the only the targeted form of Ablavar became
difficult since contrast from unenhanced tissues and non-targeted Ablavar were still
present. A post- minus pre-Ablavar injection (Fig. 3.4 D) nicely defined regions where
the contrast agent was present; however it was only the final dreMR image that showed
regions where Ablavar was targeted to albumin. The in vivo dreMR images showed an
increase in contrast around the periphery of the tumours (Fig. 3.4 F, Fig. 3.5 E and G).
The presence of the two phantoms placed beside the mouse during imaging served as
dreMR contrast controls and showed the contrast from the dreMR images were due to
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only the targeted form of Ablavar. Without histological examination, characterizations
about the tumour and surrounding vascular environment were not feasible.
The double inversion recovery (DIR) dreMR sequence differs from the single
inversion subtraction dreMR technique such that the DIR method can directly prepare
magnetization based upon

without any image post-processing. During the preparatory

section of the dreMR-DIR pulse sequence, two

(±0.221 T) field-shifting pulses and

two 180° RF pulses are applied prior to the start of the image acquisition sequence. The
DIR preparatory pulse sequence was similar to standard inversion recovery pulse
sequences that were meant to minimize sample magnetization from fat and water (51).
The DIR preparatory pulse sequence was applied to maximize the magnetization
dependence of

and minimize the magnetization dependence of

before the start of

image acquisition (4). The three periods within the preparatory phase (P1 time, P2 time,
and P3 time) were optimized for magnetization evolution producing contrast only from
of the targeted form of the Ablavar, and to suppress any contrast resulting from
sample tissues and the non-targeted form of Ablavar (4). The

dependence was a

strong indication of Ablavar-albumin binding and the dreMR-DIR image presented
contrast the localized targeted binding. The resulting image intensity depended on factors
including the concentration of albumin and Ablavar, proton density and magnitude of the
dreMR magnetic field shift. The dreMR-DIR image of a healthy mouse presented in
figure 3.6 B and C, showed dreMR contrast in the kidneys and bladder due to the time
differences between the injection of Ablavar and the image acquisition (40 minutes) and
fast clearance of the contrast agent.
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4.2 Limitations and Future Work
We identified a number of limitations within the scope of the initial in vivo dreMR
imaging analysis and results that motivate the future direction of dreMR imaging. Areas
of interest include: Ablavar bio-distribution and quantification, histological and
immunohistochemical characterization of the tumour vascular environment, and
improving the dreMR imaging technique.

4.2.1 Ablavar Binding and Relaxivity
The development of Ablavar towards FDA-approval for use as an MRI
intravascular contrast agent has been focused and optimized for use in humans (12, 19,
52), and as such, the albumin binding affinities and relaxivities exhibit a species
dependence. Ablavar was designed to bind strongly and reversibly with human serum
albumin in plasma, allowing for long vascular retention and plasma half-life (52), and an
relaxivity increase 6-10 times that of Gd-DTPA (19, 52). However, because the albumin
binding is reversible, the relaxivity will depend on dose and time of injection, and species
binding affinities. Not only does the total volume fraction albumin vary among species,
but the binding affinity for albumin can impact how translatable an animal model to
clinical settings is that depends on these factors. The affinity with purified albumin at
fixed concentrations exhibit no species dependences, however Ablavar binding in plasma
serum albumin is greatest in humans (91%) compared to dogs, rats and mice (~60%) (i.e.
binding for HSA > pig SA ~ rabbit SA > dog SA ~ rat SA ~ mouse SA) (20). These
factors also impact the relaxivity among species of Ablavar binding in blood plasma
(relaxivity in human > pig > dog ~ rabbit ~ rat ~ mouse) (20). The differences in
relaxivities of Ablavar across species have been attributed to the protein binding and
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changes in the water exchange rate (29, 52, 53). These factors limited the ability for
quantification of albumin with the dreMR contrast vials. The dreMR contrast vials used
for the in vivo murine experiments contained rabbit serum albumin, and while the dreMR
image showed contrast for only the targeted form of Ablavar with rabbit serum albumin,
it was not possible to make appropriate quantification of the in vivo dreMR contrast due
to the Ablavar pharmacokinetic species dependence.
Ablavar has previously been used to study different disease states in murine
models, including a glioma model to examine contrast enhancement and doseeffectiveness of Ablavar compared to OptiMARK (gadoversetamide), an extracellular
gadolinium-based MRI contrast agent (54), and an inflammatory lesion model to examine
inflammatory changes in the kidneys that leads to lupus nephritis (53) While the slow
buildup and long vascular retention in tumours of Ablavar will lead to contrast
enhancement, the use of a murine model will be less representative to predict the behavior
of Ablavar in humans. The ability for dreMR to detect the small and sensitive tumour
and vascular changes in a murine model would however be scalable for humans, where
the binding kinetics and relaxivities of Ablavar are greatest.

4.2.2 Correlation with Histology and Visualizing Vascular
Permeability
An important area of any research using animal models is the correlation of the
experimental images with histology and/or immunohistochemistry. Due to the limited
number of animals used thus far for the initial dreMR in vivo experiments, we were
unable to perform appropriate histological characterization of the tumour and surrounding
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tumour vascular environment. Through further investigations of the albumin uptake of
the tumour and surrounding vascular environment, and by observing and examining the
differences of the tissue and tumour morphologies over time, we can begin to understand
the changes in contrast observed with the dreMR images.

Angiogenesis plays an

important role in the progression, growth, and metastasis of tumours (55). The ability to
measure, monitor, and understand their underlying molecular mechanisms can impact
clinical therapies and patient outcomes. Macromolecular contrast media can provide a
means for imaging and quantifying angiogenesis and tumour permeability (56-60). Due
to the tendency of tumours to grow vascular networks quickly to feed their large energy
demands, angiogenic vessels become permeable to macromolecular contrast media,
where as non-diseased vessels do not (55, 61, 62). Albumin has previously been shown
to have an increased speciﬁcity to tumour development and response to therapies (24, 25,
61, 63). The ability for albumin to extravasate through permeable vessels into tumours
makes it useful as a targetable molecule for tumour detection and characterization (61).
Histological examinations of the albumin-Ablavar complex can be achieved using
fluorescein microscopy of an avidin-biotin complex stain, which would yield a
representation of the tumour and tumour vascular permeability (64, 65). Dafni et. al.
(2003) have previously used triply labeled albumin with biotin, rhodamine, and GdTPA
to show the feasibility to detect by histology, flurescence, MRI, and inductively coupled
plasma mass spectrometry the clearance of interstitial macromolecular plasma proteins
after their extravasation from permeable blood vessels (66).
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4.2.3 Imaging Technique Improvements
The sensitivity of our study was limited primarily by the binding affinities and
relaxivities of Ablavar to albumin, but also the ability to apply the appropriate field
normalizations to the positive and negative T1-weigthed images to acquire the dreMR
images.

Small image-offset errors can create imperfect normalizations and image

registrations, reducing the final quality and accuracy of the dreMR image (4, 27, 67, 68).
The inability to suppress non-targeted contrast media and native tissues would lead to
image artifacts and result in artificial dreMR contrast. The largest source causing image
shifting errors was the occurrence of eddy currents induced by the fast switching of the
field-cycling dreMR B0 insert coil. The ability to compensate and correct for the presence
of eddy currents eliminates the necessity to insert a delay time period between the
preparatory stage of the pulse sequence and start of image acquisition, thereby increasing
the available magnetization (created in the preparatory stage of the pulse sequence) for
dreMR contrast.
There are two available methods for eddy current compensation: (1) waveform
pre-emphasis, and (2) dynamically adjusting the MRI system frequency. Waveform preemphasis requires additional hardware implementation, control and synchronization with
the imaging pulse sequence, and high fidelity amplifiers (51). Dynamically adjusting the
system frequency requires the ability to modulate the pulse sequence before imaging
(integrating another preparatory stage to the pulse sequence) to compensate and minimize
the offset between the Lamor frequency and system reference frequency (67). Both
methods require prior knowledge of the temporal behavior of the eddy current for
implementation.

Hoelscher et al. (67) have recently integrated an eddy current
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compensation for dreMR imaging by dynamic phase modulation called eDREAM
(Dynamic Reference Phase Modulation). The approach uses a time varying phase that is
added to the RF pulse and acquisition window to dynamically correct for the frequency
offset. An eddy current compensation with waveform pre-emphasis is currently under
investigation to improve the dreMR imaging technique. The approach uses a currentcontrolled Helmoltz magnet pair wound around the diameter of the dreMR insert coil,
which is dynamically synchronized to create a time-varying frequency offset at the end of
the dreMR magnetic field shift (immediately before image acquisition) to compensate for
the presence of the eddy current.

4.3 Conclusion
The development and application of dreMR for field-cycling contrast was
demonstrated for in vivo imaging. The overarching theme of this thesis was to extend the
previous work of Alford et. al. (4) to develop and integrate dreMR towards an in vivo
diseased animal model. Field-cycling relaxometry techniques were used to measure and
characterize the relaxivity of the targeting contrast agent Ablavar, demonstrating a
relaxivity magnetic field dependence for only the targeted form with albumin. New
dreMR hardware and pulse sequences were synchronized and implemented to examine
the Albavar-albumin binding to distinguish only the targeted form of the contrast agent.
The dreMR imaging techniques greatly increases the ability to produce MR contrast
localized to the sites where Ablavar was targeted with albumin. Imaging with dreMR can
produce dreMR contrast by way of two techniques: (1) dreMR single inversion
subtraction technique, and (2) dreMR double inversion recovery. Any targetable contrast
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media that exhibits relaxivity magnetic field dependence can be utilized with dreMR
imaging. Development and understanding of current and emerging biomarkers can be
enhanced by the increased specificity of dreMR imaging, which can lead to effective
strategies for cancer staging through a new method of molecular imaging.
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Appendix B – Animal Protocol

Dr. Timothy Scholl
Associate Scientist, Robarts Research Institute
Assistant Professor, Department of Medical Biophysics
Schulich School of Medicine and Dentistry
Western University
___________________________________________
Begin forwarded message:

From:
Subject: eSirius Notification - New Protocol Modification Has Been APPROVED2011-085::1
Date: 8 August, 2012 4:34:05 PM EDT
To:

AUP Number: 2011-085
PI Name: Scholl, Timothy
AUP Title: Development of Metabolic Probes for Magnetic Resonance Imaging of Mouse Models of Cancer
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2011-085 has been approved.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety,
radiation safety, general laboratory safety) comply with institutional safety standards and have received all
necessary approvals. Please consult directly with your institutional safety officers.
Submitted by: NTM, Support
on behalf of the Animal Use Subcommittee
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Sep 09-Apr 10 Undergraduate Research Thesis, CT-Guided Robotic Lung Biopsy
Ryerson University, Toronto, ON, Canada
May 08-Sep 09 Undergraduate Research Assistant, Applied Modern Physics Group, P-21
Superconducting Quantum Interference Device (SQUID) Team
Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
Supervisor: Michelle Espy, PhD

LEADERSHIP AND VOLUNTEER WORK
Mar 07-May 08 Lead Facilitator, Visions of Science
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Sep 07 - Apr 08 Mentor, Tri-Mentoring Program
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EXTRACURRICULAR ACTIVITIES
Sep 07 - Apr 08 Vice-President Social Life and Events (Elected)
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